Objective Determining the prognoses of patients with acute ischemic stroke is difficult. Therefore, the aim of this study was to evaluate whether the combined assessment of plasma N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and the National Institutes of Health Stroke Scale (NIHSS) variables is relevant to the prognosis of patients with acute cerebral ischemic infarction in-hospital. Methods We enrolled 122 patients who were within three days of onset of acute ischemic stroke. We measured the plasma NT-pro-BNP level of each patient within 72 hours and recorded the NIHSS score on admission. The factors associated with death were investigated using a multivariate logistic regression analysis. Results Twenty-three patients (18.85%) died during hospitalization. The frequency of atrial fibrillation (AF), the NIHSS score on admission (8.69±4.87 in the survival group vs. 14.48±2.54 in the deceased group, p<0.001) and the plasma NT-pro-BNP level (median: 926.30 pg/mL in the survival group vs. 3,280 pg/mL in the deceased group, p<0.001; Lg NT-pro-BNP 2.82±0.66 in the survival group vs. 3.46±0.52 in the deceased group, p<0.001) were each significantly higher in the deceased group than in the survival group. The optimal cut-off levels for the NT-pro-BNP level and NIHSS score to distinguish the deceased group from the survival group were 1,583.50 pg/mL and 12.5, respectively. Patients with both elevated NT-pro-BNP levels (>1,583.50 pg/mL) and NIHSS scores on admission (NIHSS >12.5) had a substantially higher mortality rate than those without elevated NT-pro-BNP levels and NIHSS scores (89.47% vs. 9.84%, p<0.001). A multivariate logistic regression analysis demonstrated that a NT-pro-BNP level >1,583.50 pg/mL (OR, 5.001; 95% CI, 1.233 to 20.287, p=0.024) and a NIHSS score >12.5 (OR, 1.465; 95% CI, 1.191 to 1.801, p<0.001) were each independent factors associated with in-hospital death. Conclusion The plasma NT-pro-BNP level and the NIHSS score added independent and incremental contributions to the prognostic stratification of patients with acute ischemic stroke.
Introduction
The natriuretic peptides, specifically B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), have shown promise in clinical practice. BNP is synthesized in the cardiac atrial (1) and ventricular myocardium (2) . NT-pro-BNP is released when BNP is cleaved from its precursor pro-BNP after the stimulation of cardiomyocytes in response to volume or pressure overload or inflammation. The rapid measurement of the plasma BNP or NT-pro-BNP levels has been shown to increase the diagnostic accuracy of heart failure exacerbations. In additional, elevated plasma concentrations of BNP have been reported in other cardiac diseases such as atrial fibrillation (AF) (3), myocardial infarction and essential hypertension (4) . Therefore, BNP and NT-pro-BNP have emerged as important cantionship exists between elevated levels of natriuretic peptides and the acute phase of ischemic stroke (8) (9) (10) . The plasma BNP level on admission can predict in-hospital death in patients with acute ischemic stroke (8) . The plasma NT-pro-BNP level peaks the day after onset of symptoms in patients with acute ischemic stroke (11) and can be used to predict the short-term outcome of an acute stroke (12) . Furthermore, NT-pro-BNP concentrations measured during the stable phase after acute ischemic stroke are strongly predictive of long-term mortality (9) . However, to our knowledge, previous studies lack the prognostic value of combining the level of NT-pro-BNP and the National Institutes of Health Stroke Scale (NIHSS) score in patients with acute ischemic stroke in-hospital.
The aim of the present study was to investigate whether the combined assessment of the plasma NT-pro-BNP level and the NIHSS score obtained on admission in acute cerebral ischemic patients could serve as a useful predictor of in-hospital death. In addition, we explored the relationship between the NT-pro-BNP level and stroke subtype.
Materials and Methods
We enrolled consecutive patients who were within three days of the onset of acute ischemic stroke between September 2008 and July 2010. A diagnosis of acute ischemic stroke was made by stroke neurologists and confirmed with computed tomography (CT) or magnetic resonance imaging (MRI). Patients with chronic renal failure, a history of ischemic heart disease, chronic heart failure, transient ischemic attack or intracerebral or subarachnoid hemorrhage were excluded from the present study. In each case, past and present clinical histories, including medication use, were obtained by interviewing the patient or a family member in cases where the patient was aphasic or unconscious. Each patient's hospital records were also reviewed for the medical history. All patients underwent comprehensive clinical evaluation, blood pressure measurement, standard ECG, chest Xray and biochemical analyses. The stroke patients underwent CT of the brain, and the NIHSS scores of these patients were determined on admission. Stroke subtypes were classified according to the TOAST as cardiac embolism, other or unknown cause of stroke. The subjects were divided into groups according to the size of infarction observed on CT (referent to Pullicino (13) ): large infarction group (>10 cm 3 ), middle infarction group (4.1-10 cm 3 ) and small infarction group (! 4 cm 3 ). The blood samples for the analysis of NTpro-BNP were obtained within 72 hours of admission. The assay was performed as previously described (14) . The healthy control population consisted of ten subjects (five men, 50%) with normal echocardiography readings, no medication use and no symptoms of cardiac or neurological disease reported in the interview. The study was approved by the local ethics committee and informed consent was obtained from each patient or a family member.
Statistical analyses
Continuous variables are expressed as the mean ± the SD and categorical variables are reported in percentages. Statistical intergroup differences were analyzed with the chisquare test, two independence t test, one-way ANOVA and least significant difference t (LSD-t) test. We selected log10 NT-pro-BNP (Lg NT-pro-BNP) levels, which were normally distributed, for analysis because the plasma NT-pro-BNP levels were not normally distributed. We examined the sensitivity and specificity of various cut-off values of the independent predictive factors for predicting survival and created receiver operating characteristic (ROC) curves. Correlations between the two parameters were determined using a simple linear regression analysis. A multivariate logistic regression analysis was performed to identify any independent factors of stroke prognosis, including the following variables: NTpro-BNP levels, NIHSS scores, the presence of AF and infarction volumes. The statistical analyses were performed using a commercially available software package (SPSS, version 13). Values of p<0.05 were considered to be significant.
Results
A total of 122 patients (69 men, 56.6%) were enrolled in the present study. The mean age was 71.5±9.8 years. The mean ± SD of the total group NIHSS scores obtained on admission and the Lg NT-pro-BNP levels were 9.78±5.06 and 2.94±0.69, respectively. The median NT-pro-BNP concentration for the entire group was 1,035.50 pg/mL (25th to 75th percentiles: 246.70 to 3,105.25). The mean age of the healthy control group was 73.8±6.7 years. The median NTpro-BNP level was 248 pg/mL (25th to 75th percentiles: 175.60 to 344.90) and the median LgNT-pro-BNP level was 2.37±0.25. The primary outcome measurement was death. Mortality data were obtained according to the results observed during hospitalization. Twenty-three patients (18.85%) died during hospitalization. The causes of death were as follows: brain edema and cerebral hernia in 20 patients, congestive heart failure in two patients and acute renal failure in one patient. Table 1 shows the characteristics of the survival and deceased groups. The characteristics, including age, gender and the presence of hypertension and diabetes mellitus did not differ between the survival group and the deceased group (all p>0.05). In the present study, the presence of AF was a factor for cardiac embolism stroke, and stroke subtypes were classified into an infarction with AF group and an infarction without AF group. The frequency of AF (39.4% for the survival group vs. 73.9% for the deceased group, p=0.003), the NIHSS score on admission (8.69±4.87 vs. 14.48±2.54, p<0.001), the NT-pro-BNP level (median: 926.30 vs. 3,280 pg/mL, p<0.001) and the Lg NT-pro-BNP level (2.82±0.66 vs. 3.46±0.52, p<0.001) were each significantly lower in the survival group than in the deceased Furthermore, we compared the plasma NT-pro-BNP levels and the clinical NIHSS scores in different stroke subtypes ( Table 2 ). The mean ± SD of the plasma Lg NT-pro-BNP level of the infarction with AF group was significantly higher than that of the infarction without AF group (3.37± 0.42 vs. 2.57±0.66, p<0.001). Among the different volumes in the infarction groups, the plasma Lg10 NT-pro-BNP level in the large infarction group was the highest (large infarction 3.29±0.58 vs. middle infarction 2.75±0.65, p<0.001; large infarction 3.29±0.58 vs. small infarction 2.37±0.44, p< 0.001). At the same time, the mean ± SD of the clinical NIHSS scores of the infarction with AF group was significantly higher than that of the infarction without AF group (10.89±4.36 vs. 8.83±5.44, p=0.024). A comparison of the clinical NIHSS scores among the three different volumes of infarction groups showed statistical significance (p<0.001). According to the results of the least significant difference t (LSD-t) test, the NIHSS scores on admission were significantly higher in the large infarction group than in the small infarction group (11.60±4.58 vs. 3.84±3.39, p<0.001) and in the middle infarction group than in the small infarction group (11.00±3.33 vs. 3.84±3.39, p<0.001), respectively. In contrast, the comparison between the large infarction group and the middle infarction group did not show any statistical differences (p=0.478).
Previous researchers have shown that the NT-pro-BNP level can be used to predict the outcome of acute stroke and cardiovascular disease (12, 15) . We therefore explored the diagnostic utility of the NT-pro-BNP level and the NIHSS score at different cut-off values. The optimal cut-off point for the NT-pro-BNP level as determined by the ROC analysis was 1,583.50 pg/mL (sensitivity 82.6%, specificity 70.7%, area under the curve 0.788, 95% confidence interval 0.683 to 0.892; Table 3 and Fig. 1 ). This value was slightly higher than the median NT-pro-BNP level of 1,035.50 pg/ mL for the total group. The optimal cut-off level, sensitivity and specificity of the NIHSS score to distinguish the deceased group from the survival group were 12.5, 82.6% and 77.8%, respectively (area under the curve 0.852, 95% confidence interval 0.781 to 0.923; Table 3 and Fig. 2 ).
In addition, we divided the total population into two groups according to the cut-off values of the NT-pro-BNP level and the NIHSS score, respectively (Table 4) . Patients with an NT-pro-BNP level <1,583.50 pg/mL or an NIHSS score <12.5 had a significantly improved survival rate. In contrast, the patients with an NT-pro-BNP level >1,583.50 pg/mL or an NIHSS score >12.5 had a poorer prognosis and suffered a higher mortality rate (37.5% and 46.34%, respectively). The frequency of AF (24.32% vs. 79.17%, p<0.001), the NIHSS score on admission (8.6±5.1 vs. 11.4±4.6, p= 0.002) and the LgNT-pro-BNP level (2.51±0.52 vs. 3.60± 0.25, p<0.001) were each significantly lower in the low level group (<1,583.50 pg/mL) than in the high level group (>1,583.50 pg/mL). However, no differences were observed in the other variables. The results indicated a strong association between the NT-pro-BNP level and outcome, with a prognostic value that was stronger than that of conventional stroke risk factors. Interestingly, a similar conclusion could be drawn from the NIHSS groups. However, it is more important that the patients with both elevated NT-pro-BNP levels (>1,583.50 pg/mL) and elevated NIHSS scores on admission (NIHSS >12.5) had a substantially higher mortality rate than those without elevations in NT-pro-BNP levels and NIHSS scores [(17/19, 89 .47%) vs. (6/61, 9.84%)].
The plasma NT-pro-BNP level was significantly associated with gender, the presence of AF and the stroke subtype (p<0.001). Furthermore, the plasma BNP level was positively correlated with clinical variables such as the NIHSS score on admission (r=0.259, p=0.004). Likewise, the NIHSS score was significantly associated with the NT-pro-BNP level, the presence of AF and the stroke subtype (p< 0.001). This indicated that as the stroke severity, which was assessed using the NIHSS scores, became more severe, the plasma NT-pro-BNP level increased and the stroke outcome became worse. The plasma NT-pro-BNP level, NIHSS score on admission, infarction volume and the presence of AF were chosen as possible admission factors associated with in-hospital death. In a multivariate logistic regression analysis using these variables, an NT-pro-BNP level >1,583.50 pg/mL (OR, 5.001; 95% CI, 1.233 to 20.287, p=0.024) and an NIHSS score >12.5 (OR, 1.465; 95% CI, 1.191 to 1.801, p<0.001) were found to be independent predictors of acute ischemic stroke mortality (Table 5) .
Discussion
The present study demonstrated that the NT-pro-BNP level and the NIHSS score are independent predictors of the prognosis of patients with acute ischemic stroke. The acute ischemic stroke patients with both elevated NT-pro-BNP levels (>1,583.50 pg/mL) and elevated NIHSS scores on admission (NIHSS >12.5) had a higher mortality rate than those without elevated NT-pro-BNP levels and elevated NIHSS scores in-hospital. Therefore, the combination of both an elevated NT-pro-BNP level and an elevated NIHSS score should be a useful predictor for the prognosis of patients with acute ischemic stroke.
Recently, acute-phase levels of NT-pro-BNP have been reported to be associated with mortality in patients with acute ischemic stroke (9, 16) . It has been well established that acute stroke is associated with a higher prevalence of associated acute cardiovascular effects, including left ventricular dysfunction, and is strongly associated with prevalent AF, which is expected to increase the NT-pro-BNP level in a prognostically meaningful manner (9) . In contrast, in the setting of acute stroke, the prognostic value of the NT-pro-BNP level in the context of acute stroke may reflect volume expansion or pressure overload in which the resulting wall stress initiates the synthesis of natriuretic peptides in the ventricular myocardium (9) . In the present study, the plasma NT-pro-BNP levels were significantly higher in ischemic stroke patients with AF than in those without AF. More patients with a concentration of NT-pro-BNP >1,583.50 pg/mL suffered from AF. Our results suggest that the BNP level in acute ischemic stroke patients without clinical heart failure is frequently elevated, particularly in those with cardioembolic stroke (17) . Another factor affecting the NT-pro-BNP level is the difference in the size of infarction. It appears that the plasma NT-pro-BNP level is positively correlated with the volume of infarction. Likewise, patients with NIHSS scores >12.5 had higher NT-pro-BNP levels than patients with NIHSS scores <12.5. The patients with NIHSS scores >12.5 suffered from AF more frequently. The results of this study indicate a strong association between the NTpro-BNP level and outcome, with a prognostic value that is stronger than that of conventional stroke risk factors. It is more important that patients with both elevated NT-pro-BNP levels (>1,583.50 pg/mL) and elevated NIHSS scores on admission (NIHSS >12.5) had a substantially higher mortality rate than those without elevated NT-pro-BNP levels and elevated NIHSS scores. The multivariate logistic regression analysis showed that both elevated NT-pro-BNP levels and elevated NIHSS scores are independent predictors of acute ischemic stroke mortality in-hospital. In a study by Shibazaki et al. (8) , the plasma BNP level on admission was found to predict in-hospital death in patients with acute ischemic stroke. Previous studies have demonstrated that the plasma NT-pro-BNP level is a predictor of long-term mortality after acute ischemic stroke (9) . Therefore, our data further highlight the importance of the NT-pro-BNP level in patients with acute ischemic stroke. So far, substantial research has demonstrated that not only does the NT-pro-BNP level predict the likelihood of ischemic stroke (18, 19) and the potential for early hazards after acute ischemic stroke (11, 12) , it also serves as a useful tool for predicting the prognosis distant from the index event (16) . There exists a strong association between the NT-pro-BNP level and patient outcomes. Therefore, the plasma NT-pro-BNP level is a useful biological marker for predicting the likelihood of ischemic stroke and determining the prognosis of patients in the acute phase and those with short-term or long-term ischemic stroke. Furthermore, the present study demon- Table 4 . Clinical Characteristics of Study Subjects according to the NT-pro-BNP and NIHSS Table 5 . Multivariate Logistic Regression Analysis Models for Probability Mortality in-Hospital strated that the combined assessment of both elevated NTpro-BNP levels and elevated NIHSS scores may be a greater power predictor of the prognosis of acute ischemic stroke, at least in-hospital.
It is worthwhile to place our results in context with those of other investigations of NT-pro-BNP. The mean concentration of NT-pro-BNP in the present analysis was considerably higher than that of previous studies (12, 14) . The reasons for this disparity include many factors. To our knowledge, conditions such as left ventricular dysfunction (20, 21) , AF (3, 15) , heart failure (22-24), older age (25) and renal dysfunction (26) are known causes of increased natriuretic peptides. In addition, race is a potential factor. The limitations of our study include the fact that we lack the comprehensive results of a systematic evaluation of cardiac morphological and functional abnormalities performed with echocardiography. In addition, the consciousness level (27) and other biochemical markers such as D-dimer (28), Creactive protein (29) and albumin levels (30) are helpful in evaluating the prognosis of patients in the acute phase of ischemic stroke. Finally, the sample size was small. A larger study is therefore required to confirm our hypotheses.
Conclusion
In conclusion, our findings suggest that acute ischemic stroke patients with both elevated NT-pro-BNP levels >1,583.50 pg/mL and elevated NIHSS scores >12.5 on admission have poorer outcomes than those without elevated NT-pro-BNP levels and elevated NIHSS scores. Therefore, the combined assessment of both elevated NT-pro-BNP levels and elevated NIHSS scores is effective in predicting the outcomes of patients with acute ischemic stroke. Further study is required to ascertain the predictive ability of this combined assessment.
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